Lupin Limited has announced its unaudited financial results for the second quarter of FY27, ending September 30, 2026. The company reported Net Sales of ₹77,855 million, marking a 14.0% year-on-year growth. EBITDA stood at ₹19,574 million, a decrease of 8.4% YoY, while Net Income was ₹11,553 million, down 21.8% YoY. The presentation also provided a detailed breakdown of performance across various business segments and geographies.
Lupin Announces Q2 FY27 Financial Performance
Lupin Limited has officially released its financial results for the second quarter of the fiscal year 2027 (Q2 FY27), which concluded on September 30, 2026. The company disclosed key financial metrics, including net sales, gross profit, EBITDA, and net income, highlighting both year-over-year (YoY) and quarter-over-quarter (QoQ) performance trends.
Key Financial Highlights for Q2 FY27
In Q2 FY27, Lupin reported Net Sales of ₹77,855 million, representing a substantial 14.0% increase compared to the same period in the previous fiscal year (Q2 FY26). However, EBITDA saw a decrease of 8.4% YoY, amounting to ₹19,574 million. The company’s Net Income for the quarter was reported as ₹11,553 million, reflecting a 21.8% decrease from Q2 FY26. Compared to the preceding quarter (Q1 FY27), Net Sales decreased by 5.3%, EBITDA by 20.5%, and Net Income by 18.4%.
First Half FY27 Performance
For the first half of FY27 (H1 FY27), Lupin’s Net Sales reached ₹160,028 million, a significant 23.1% growth compared to H1 FY26. EBITDA for H1 FY27 was ₹44,209 million, up 17.0% YoY. Net Income for the first half stood at ₹25,703 million, a 4.7% decrease YoY.
Business Performance and Key Metrics
The investor presentation detailed key growth metrics for Q2 FY27, indicating steady operating performance. Total sales for the quarter were ₹77,855 million, a 14% YoY increase. EBITDA margin was 25.1%, and Net Income was ₹11,553 million, with a 22% YoY decline. Business performance was broken down by region, with North America contributing ₹31,696 million (+10% YoY), India at ₹23,836 million (+15% YoY), and APAC at ₹4,273 million (+43% YoY).
Key Developments and Strategic Focus
Lupin highlighted several key developments, including new product launches and approvals. The company secured tentative approval from the U.S. FDA for Apixaban Oral Suspension 505(b)(2) and launched Sugammadex Injection in the US. Business development initiatives involved strategic partnerships and the spin-out of oncology programs. Compliance efforts included successful FDA inspections and remediation at various sites.
Financial Snapshot and Market Position
The sales mix for Q2 FY27 shows the United States as the largest market at 39% (₹30,202 million), followed by India at 31% (₹23,836 million). Other Developed Markets accounted for 15% (₹11,823 million), Emerging Markets for 11% (₹8,908 million), and API for 4% (₹3,086 million). The company maintains a strong focus on R&D, Capex, and optimizing its Net Debt to Equity ratio.
Source: BSE
